Top Markets
Coin of the day
Hemostemix Inc. Hemostemix Inc.

Hemostemix Inc.

HEM
Rank in Stocks #32158
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Share Price
$0.05504527
Last synced: 2026-08-17
Market Cap
$10.89M
Change (1 day)
15.38%
Change (1 year)
-10.64%
Country
CA
Trade Hemostemix Inc. (HEM)

Category

Number of shares outstanding for Hemostemix Inc. (HEM)
Number of shares outstanding as of August 2026: 0
According to Hemostemix Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Hemostemix Inc. (HEM) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
483.58M -
AU
- -
CH
- -
KR